• Meeting Mic

  • By: Healio
  • Podcast

Meeting Mic

By: Healio
Listen for free

  • Summary

  • While annual major scientific meetings are the venue to stay up-to-date in your clinical area, it is near impossible to attend all breaking news sessions. Through interviews with experts, Healio’s Meeting Mic provides a post-meeting wrap-up of the most important content that listeners can consume on-the-go.
    Show more Show less
Episodes
  • Highlights from ASCO Annual Meeting 2024, Leukemia Edition, Continued

    Highlights from ASCO Annual Meeting 2024, Leukemia Edition, Continued
    Jul 3 2024

    In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.

    Andrew Hantel, MD, discusses results of a study on racial disparities in acute myeloid leukemia trials. :27

    Christine McMahon, MD, discusses results of the phase 3 ASC4FIRST study, which examined asciminib versus tyrosine kinase inhibitors for patients with newly diagnosed chronic-phase CML. 3:30

    Andrew Hantel, MD, discusses researching inequities in acute myeloid leukemia treatment in historically marginalized communities. 4:35

    Christine McMahon, MD, presents results of a randomized trial of a care model for patients with acute myeloid leukemia and myelodysplastic syndrome. 7:09

    Christine McMahon, MD, highlights the ACCESS study into post-transplant graft-versus-host disease, which produced “impressive” rates of post-transplant overall survival at 1 year. 10:22

    Read the full coverage here:

    https://www.healio.com/news/hematology-oncology/20240625/video-a-patients-raceethnicity-affects-eligibility-for-acute-myeloid-leukemia-trials

    https://www.healio.com/news/hematology-oncology/20240620/video-strong-results-for-asciminib-in-chronic-myelogenous-leukemia

    https://www.healio.com/news/hematology-oncology/20240625/video-treatment-delays-do-not-lead-to-acute-myeloid-leukemia-survival-disparities

    https://www.healio.com/news/hematology-oncology/20240620/video-palliative-care-model-increases-quality-of-life-for-patients-with-leukemia

    https://www.healio.com/news/hematology-oncology/20240620/video-study-produces-impressive-posttransplant-graftversushost-disease-survival-rates

    Disclosures:

    Hantel reports no relevant financial disclosures.

    McMahon reports receiving institutional funding from Syndax and Syros and serving on a safety monitoring committee for Kura Oncology.
    Show more Show less
    13 mins
  • Highlights from ASCO Annual Meeting 2024, Leukemia Edition

    Highlights from ASCO Annual Meeting 2024, Leukemia Edition
    Jun 19 2024

    In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting with a focus on leukemia, as well as Healio’s top headlines from the meeting.

    Jorge E. Cortes, MD, discusses how asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia. :27

    Oreofe O. Odejide, MD, MPH, highlights the importance of this study. 3:30

    Read the full coverage here:

    https://www.healio.com/news/hematology-oncology/20240531/asciminib-may-transform-treatment-paradigm-for-chronic-myeloid-leukemia

    New approach ‘redefining what is a suitable donor’ for stem cell transplant

    Source: Al Malki MM, et al. Abstract 6503. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago.

    Disclosures:

    Cortes reports research funding to his institution from or consultant/advisory roles with Gilead Sciences, Jazz Pharmaceuticals, Novartis, Pfizer, Takeda and other companies.
    Show more Show less
    11 mins
  • Highlights from ASCO Annual Meeting 2024

    Highlights from ASCO Annual Meeting 2024
    Jun 18 2024
    In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting. Joseph A. Greer, PhD, discusses how early palliative care via telehealth had an equivalent impact on quality of life as in-person visits for patients with advanced non-small cell lung cancer. :27 Charu Aggarwal, MD, MPH, FASCO, further discusses these findings during a press briefing. 3:30 Heinz-Josef Lenz, MD, shares his thoughts on the first-line immunotherapy combination of nivolumab and ipilimumab in colorectal cancer. 4:35 Fumiko Chino, MD, discusses findings on the need for a more effective and transparent prior authorization process to ensure patients receive timely access to essential pain management. 7:09 Suneel Kamath, MD, provides an overview of findings assessing how the microbiome profile of early-onset pancreatic adenocarcinoma is distinct from that of average-onset disease. 10:22 Julie R. Gralow, MD, FACP, FASCO, discusses the important implications of a prospective study on young breast cancer survivors who attempted pregnancy and became pregnant. 12:54 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20240602/we-have-the-technology-telehealth-increases-access-to-palliative-care-for-cancer https://www.healio.com/news/hematology-oncology/20240602/practicechanging-data-support-firstline-immunotherapy-combination-in-colorectal-cancer https://www.healio.com/news/hematology-oncology/20240531/findings-highlight-need-to-improve-prior-authorization-process-for-cancer-pain-management https://www.healio.com/news/hematology-oncology/20240603/tumor-microbiome-profiles-in-pancreatic-cancer-differ-by-age-of-onset https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets Glucose-lowering drugs reduce risk for obesity-related cancers Source: Lin CH, et al. Abstract 10508. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago. Chemotherapy regimen improves survival in advanced esophageal cancer Source: Hoeppner J, et al. Abstract LBA1. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago. Disclosures: Chino reports no relevant financial disclosures. Greer reports a consulting role with BeiGene; research funding from Blue Note Therapeutics and NCCN/AstraZeneca; and royalties from Oxford University Press and Springer Publishing Company. Please see the abstract for all other researchers’ relevant financial disclosures.[JJ1] Kamath reports no relevant financial disclosures. Lenz reports honoraria from, consulting/advisory roles with, or travel, accommodations or expenses from 3T Biosciences, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Fulgent Genetics, G1 Therapeutics, GSK, Isofol Medical, Jazz Pharmaceuticals, Merck Serono, Oncocyte and Roche. Please see the abstract for all other researchers’ relevant financial disclosures.
    Show more Show less
    20 mins
Physical Illness & Disease Biological Sciences Hygiene & Healthy Living
Show more Show less

What listeners say about Meeting Mic

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available